These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14662972)

  • 41. Sensitivity of respiratory strains of Pseudomonas aeruginosa to carbenicillin.
    May JR; Ingold A
    J Med Microbiol; 1973 Feb; 6(1):77-82. PubMed ID: 4632255
    [No Abstract]   [Full Text] [Related]  

  • 42. Dental units as infection sources of Pseudomonas aeruginosa.
    Barben J; Schmid J
    Eur Respir J; 2008 Oct; 32(4):1122-3. PubMed ID: 18827162
    [No Abstract]   [Full Text] [Related]  

  • 43. Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin.
    Ohman DE; Chakrabarty AM
    Infect Immun; 1982 Aug; 37(2):662-9. PubMed ID: 6811437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A
    Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract]   [Full Text] [Related]  

  • 45. Evolutionary insight from whole-genome sequencing of Pseudomonas aeruginosa from cystic fibrosis patients.
    Marvig RL; Sommer LM; Jelsbak L; Molin S; Johansen HK
    Future Microbiol; 2015; 10(4):599-611. PubMed ID: 25865196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients.
    Spilker T; Coenye T; Vandamme P; LiPuma JJ
    J Clin Microbiol; 2004 May; 42(5):2074-9. PubMed ID: 15131172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Airborne dissemination of transmissible bacterial species in cystic fibrosis.
    Jones AM
    Thorax; 2014 Aug; 69(8):690-1. PubMed ID: 24898016
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of tests to predict metallo-β-lactamase in cystic fibrosis (CF) and non-(CF) Pseudomonas.
    Perez LR; Limberger MF; Costi R; Dias CA; Barth AL
    Braz J Microbiol; 2014; 45(3):835-9. PubMed ID: 25477915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis.
    Pier GB; Grout M; Zaidi TS; Goldberg JB
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 2):S175-82. PubMed ID: 8876538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of adherence in the pathogenesis of Pseudomonas aeruginosa lung infection in cystic fibrosis patients.
    Woods DE; Bass JA; Johanson WG; Straus DC
    Infect Immun; 1980 Dec; 30(3):694-9. PubMed ID: 7014444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis unit.
    Denton M; Littlewood JM; Brownlee KG; Conway SP; Todd NJ
    Lancet; 1996 Dec; 348(9041):1596-7. PubMed ID: 8950918
    [No Abstract]   [Full Text] [Related]  

  • 54. Lung transplantation for non-cystic fibrosis bronchiectasis.
    Rademacher J; Ringshausen FC; Suhling H; Fuge J; Marsch G; Warnecke G; Haverich A; Welte T; Gottlieb J
    Respir Med; 2016 Jun; 115():60-5. PubMed ID: 27215505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces.
    Panagea S; Winstanley C; Walshaw MJ; Ledson MJ; Hart CA
    J Hosp Infect; 2005 Feb; 59(2):102-7. PubMed ID: 15620443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Social network analysis of Pseudomonas aeruginosa in cystic fibrosis.
    Taylor-Robinson DC; Southern KW; Winstanley C
    Lancet Respir Med; 2015 Aug; 3(8):595-6. PubMed ID: 26208995
    [No Abstract]   [Full Text] [Related]  

  • 57. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
    Tay GT; Reid DW; Bell SC
    Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.
    Knibbs LD; Johnson GR; Kidd TJ; Cheney J; Grimwood K; Kattenbelt JA; O'Rourke PK; Ramsay KA; Sly PD; Wainwright CE; Wood ME; Morawska L; Bell SC
    Thorax; 2014 Aug; 69(8):740-5. PubMed ID: 24743559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis.
    Green H; Jones AM
    Semin Respir Crit Care Med; 2015 Apr; 36(2):225-35. PubMed ID: 25826590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.